Bilateral Risk-Reducing Oophorectomy in BRCA1 and BRCA2 Mutation Carriers

Bilateral risk-reducing oophorectomy (BRRO) is widely used for cancer risk reduction in women with BRCA1 and BRCA2 (BRCA1/2) mutations. BRRO significantly reduces breast cancer risk by approximately 50% and ovarian cancer risk by 85% to 95%, but it may be accompanied by menopausal symptoms, impaired quality of life, and accelerated bone loss. Therefore, decisions regarding the timing of BRRO, the risks and benefits of a simultaneous hysterectomy, and the use of hormone replacement therapy (HRT) must be made in concert with the patient and individualized to their circumstances. However, recent data demonstrate that HRT after BRRO in unaffected premenopausal women does not negate the breast cancer risk reduction that BRRO provides. This article reviews the studies regarding BRRO in BRCA1/2 mutation carriers, with particular focus on the use of HRT.

If the inline PDF is not rendering correctly, you can download the PDF file here.

Correspondence to: Susan M. Domchek, MD, Abramson Cancer Center, University of Pennsylvania, 14 Penn Tower, Philadelphia, PA 19104. E-mail: susan.domchek@uphs.upenn.edu

References

  • 1.

    RebbeckTRLynchHTNeuhausenSL. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med2002;346:16161622.

  • 2.

    KauffNDSatagopanJMRobsonME. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med2002;346:16091615.

    • Search Google Scholar
    • Export Citation
  • 3.

    RutterJLWacholderSChetritA. Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study. J Natl Cancer Inst2003;95:10721078.

    • Search Google Scholar
    • Export Citation
  • 4.

    RebbeckTRLevinAMEisenA. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst1999;91:14751479.

    • Search Google Scholar
    • Export Citation
  • 5.

    StruewingJPWatsonPEastonDF. Prophylactic oophorectomy in inherited breast/ovarian cancer families. J Natl Cancer Inst Monogr1995;17:3335.

    • Search Google Scholar
    • Export Citation
  • 6.

    WhiteCD. Papillary intraperitoneal neoplasia resembling ovarian carcinoma after removal of benign ovaries. W V Med J1993;89:282283.

  • 7.

    KempGHsiuJAndrewsM. Papillary peritoneal carcinomatosis after prophylactic oophorectomy. Gynecol Oncol1992;47:395397.

  • 8.

    ChenKSchooleyJFlamM. Peritoneal carcinomatosis after prophylactic oophorectomy in familial ovarian cancer syndrome. Obstet Gynecol1985;66:93s94s.

    • Search Google Scholar
    • Export Citation
  • 9.

    PiverMSJishiMFTsukadaYNavaG. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer1993;71:27512755.

    • Search Google Scholar
    • Export Citation
  • 10.

    TobacmanJKGreeneMHTuckerMA. Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovariancancer-prone families. Lancet1982;2:795797.

    • Search Google Scholar
    • Export Citation
  • 11.

    SwerdlowM. Mesothelioma of the pelvic peritoneum resembling papillary cystadenocarcinoma. Am J Obstet Gynecol1959;77:197200.

  • 12.

    EisenARebbeckTRWoodWCWeberBL. Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer. J Clin Oncol2000;18:19801995.

    • Search Google Scholar
    • Export Citation
  • 13.

    FrommGGershensonDMSilvaEG. Papillary Serous carcinoma of the peritoneum. Obstet Gynecol1990;75:8995.

  • 14.

    ZhouJIwasaYKnoishiI. Papillary Serous carcinoma of the peritoneum in women. Cancer1995;76:429436.

  • 15.

    CaseyMJSynderCBewtraC. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Gynecol Oncol2005;97:457467.

    • Search Google Scholar
    • Export Citation
  • 16.

    SalazarHGodwinAKDalyMB. Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst1996;88:18101820.

    • Search Google Scholar
    • Export Citation
  • 17.

    LuKHGarberJECramerDW. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol2000;18:27282732.

    • Search Google Scholar
    • Export Citation
  • 18.

    PowellCBKenleyEChenLM. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol2005;23:127132.

    • Search Google Scholar
    • Export Citation
  • 19.

    McEwenARMcConnellDTKenwrightDN. Occult cancer of the fallopian tube in a BRCA2 germline mutation carrier at prophylactic salpingo-oophorectomy. Gynecol Oncol2004;92:992994.

    • Search Google Scholar
    • Export Citation
  • 20.

    CarcangiuMLRadicePManoukianS. Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers. Int J Gynecol Pathol2004;23:3540.

    • Search Google Scholar
    • Export Citation
  • 21.

    ColganTJMurphyJColeDE. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol2001;25:12831289.

    • Search Google Scholar
    • Export Citation
  • 22.

    AzizSKupersteinGRosenB. A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol Oncol2001;80:341345.

  • 23.

    BroseMSRebbeckTRCalzoneKA. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst2002;94:13651372.

    • Search Google Scholar
    • Export Citation
  • 24.

    ColganTJBoernerSLMurphyJ. Peritoneal lavage cytology: an assessment of its value during prophylactic oophorectomy. Gynecol Oncol2002;85:397403.

    • Search Google Scholar
    • Export Citation
  • 25.

    Nathorst-BoosJvon SchoultzBCarlstromK. Elective ovarian removal and estrogen replacement therapy—effects on sexual life, psychological well-being and androgen status. J Psychosom Obstet Gynaecol1993;14:283293.

    • Search Google Scholar
    • Export Citation
  • 26.

    PouillesJMTremollieresFBonneuMRibotC. Influence of early age at menopause on vertebral bone mass. J Bone Miner Res1994;9:311–315.

  • 27.

    FrankTSManleySAOlopadeOI. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol1998;16:24172425.

    • Search Google Scholar
    • Export Citation
  • 28.

    JohannssonOLomanNBorgAOlssonH. Pregnancy-associated breast cancer in BRCA1 and BRCA2 germline mutation carriers [letter]. Lancet1998;352:13591360.

    • Search Google Scholar
    • Export Citation
  • 29.

    Levy-LahadECataneREisenbergS. Founder/BRCA1/and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet1997;60:10591067.

    • Search Google Scholar
    • Export Citation
  • 30.

    SchragDKuntzKMGarberJEWeeksJC. Decision analysis—effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med1997;336:14651471. Erratum appears in N Engl J Med 1997;337:434.

    • Search Google Scholar
    • Export Citation
  • 31.

    NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. JAMA1995;273:491497.

    • Search Google Scholar
    • Export Citation
  • 32.

    RossouwJEAndersonGLPrenticeRL. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA2002;288:321333.

    • Search Google Scholar
    • Export Citation
  • 33.

    AndersonGLLimacherMAssafAR. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291:17011712.

    • Search Google Scholar
    • Export Citation
  • 34.

    KellyJPKaufmanDWRosenbergL. Use of postmenopausal hormone therapy since the Women's Health Initiative findings. Pharmacoepidemiol Drug Saf2005;5:5.

    • Search Google Scholar
    • Export Citation
  • 35.

    RebbeckTRFriebelTWagnerTM. Effect of short term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. J Clin Oncol2005;23:78047810.

    • Search Google Scholar
    • Export Citation
  • 36.

    ArmstrongKSchwartzJSRandallT. Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis. J Clin Oncol2004;22:10451054.

    • Search Google Scholar
    • Export Citation
  • 37.

    RussellJ. Laparoscopic oophorectomy. Curr Opin Obstetr Gynecol1995;7:295298.

  • 38.

    EscobedoLPetersonHGrubbG. Case-fatality rates for tubal sterilization in U.S. hospitals, 1979 to 1980. Am J Obstet Gynecol1989;160:147150.

    • Search Google Scholar
    • Export Citation
  • 39.

    MenczerJDanUOelsnerG. Laparoscopic prophylactic oophorectomy in women belonging to ovarian cancer prone familes. Advantages and shortcomings. Eur J Gynaecol Oncol1994;15:105107.

    • Search Google Scholar
    • Export Citation
  • 40.

    MenczerJBen-BaruchG. Familial ovarian cancer in Israeli Jewish women. Obstet Gynecol1991;77:276277.

  • 41.

    GradyDGebretsadikTKerlikowskeK. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol1995;85:304313.

    • Search Google Scholar
    • Export Citation
  • 42.

    BeralV. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet2003;362:419427.

  • 43.

    LavieOHornreichGBen-ArieA. BRCA germline mutations in Jewish women with uterine serous papillary carcinoma. Gynecol Oncol2004;92:521524.

    • Search Google Scholar
    • Export Citation
  • 44.

    ThompsonDEastonDF. Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst2002;94:13581365.

  • 45.

    NarodSABrunetJSGhadirianP. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet2000;356:18761881.

    • Search Google Scholar
    • Export Citation
  • 46.

    FisherBCostantinoJPWickerhamDL. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst1998;90:13711388.

    • Search Google Scholar
    • Export Citation

Article Information

Cited By

PubMed

Google Scholar

Related Articles

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 52 52 22
PDF Downloads 19 19 6
EPUB Downloads 0 0 0